Mahmoud Reza Jaafari Selected Research

Liposomes (Liposome)

10/2022	Designing new nanoliposomal formulations and evaluating their effects on myeloid-derived suppressor cells and regulatory T cells in a colon cancer model aiming to develop an efficient delivery system for cancer treatment; an in vitro and in vivo study.
9/2022	Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.
7/2022	Amino acid coordination complex mediates cisplatin entrapment within PEGylated liposome: An implication in colorectal cancer therapy.
2/2022	Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.
2/2022	Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy.
2/2022	Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
1/2022	Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy.
1/2022	Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes.
12/2021	pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
11/2021	Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mahmoud Reza Jaafari Research Topics

Disease

99	Neoplasms (Cancer) 10/2022 - 06/2010
33	Breast Neoplasms (Breast Cancer) 09/2022 - 01/2014
20	Carcinoma (Carcinomatosis) 04/2021 - 12/2013
17	Melanoma (Melanoma, Malignant) 01/2022 - 12/2015
16	Leishmaniasis 10/2021 - 06/2012
11	Cutaneous Leishmaniasis 10/2021 - 07/2012
8	Infections 10/2021 - 07/2012
7	Colonic Neoplasms (Colon Cancer) 07/2021 - 10/2013
6	Atherosclerosis 06/2022 - 07/2016
5	Inflammation (Inflammations) 06/2022 - 01/2019
4	COVID-19 11/2021 - 10/2020
4	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 01/2019
3	Colorectal Neoplasms (Colorectal Cancer) 07/2022 - 01/2016
3	Dyslipidemias (Dyslipidemia) 01/2021 - 05/2015
3	Hypersensitivity (Allergy) 10/2020 - 07/2015
3	Cardiotoxicity 03/2019 - 10/2013
2	Autoimmune Diseases (Autoimmune Disease) 12/2021 - 11/2021
2	Body Weight (Weight, Body) 11/2021 - 03/2019
2	Stroke (Strokes) 10/2021 - 02/2018
2	Diabetes Mellitus 01/2021 - 09/2016
2	Neoplasm Metastasis (Metastasis) 09/2020 - 09/2020
2	Wounds and Injuries (Trauma) 07/2020 - 03/2019
2	Heart Diseases (Heart Disease) 01/2020 - 03/2019
2	Hypoxia (Hypoxemia) 12/2019 - 01/2019
2	Melanosis (Freckles) 06/2019 - 09/2015
2	Head and Neck Neoplasms (Head and Neck Cancer) 03/2019 - 04/2016
2	Carcinogenesis 02/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

54	Liposomes (Liposome)IBA 10/2022 - 11/2009
44	VaccinesIBA 12/2021 - 07/2012
37	Peptides (Polypeptides)IBA 02/2022 - 07/2012
22	AntigensIBA 12/2021 - 07/2012
20	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 12/2013
14	CurcuminIBA 06/2022 - 01/2018
13	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 12/2013
11	Pharmaceutical PreparationsIBA 02/2022 - 06/2009
10	Therapeutic UsesIBA 09/2020 - 04/2015
9	LigandsIBA 02/2022 - 12/2013
9	Proteins (Proteins, Gene)FDA Link 12/2021 - 07/2012
8	EnzymesIBA 10/2021 - 11/2014
8	MicroRNAs (MicroRNA)IBA 02/2018 - 01/2016
6	1,2- dioleoyloxy- 3- (trimethylammonium)propaneIBA 10/2022 - 12/2013
6	Monoclonal AntibodiesIBA 10/2021 - 11/2015
6	CPG-oligonucleotideIBA 01/2021 - 11/2014
6	EpitopesIBA 01/2020 - 07/2012
6	1-dodecylpyridoxal (PLD)IBA 05/2019 - 12/2013
6	Biomarkers (Surrogate Marker)IBA 02/2018 - 01/2016
5	Amphotericin B (Amphotericin)FDA LinkGeneric 10/2021 - 12/2015
5	AntibodiesIBA 01/2021 - 11/2015
4	Cisplatin (Platino)FDA LinkGeneric 07/2022 - 10/2014
4	Small Interfering RNA (siRNA)IBA 01/2022 - 04/2015
4	CholesterolIBA 04/2020 - 11/2014
4	Protein Subunit VaccinesIBA 01/2020 - 01/2015
4	Phospholipids (Phosphatides)FDA LinkGeneric 08/2019 - 10/2014
4	OligodeoxyribonucleotidesIBA 07/2018 - 06/2012
3	Docetaxel (Taxotere)FDA Link 09/2022 - 09/2016
3	AntioxidantsIBA 03/2022 - 01/2018
3	LipidsIBA 02/2022 - 02/2019
3	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 11/2012
3	Biological ProductsIBA 12/2021 - 01/2016
3	CytokinesIBA 10/2021 - 11/2014
3	galbanic acidIBA 07/2021 - 01/2019
3	arginyl-glycyl-aspartic acidIBA 07/2021 - 12/2013
3	Nucleotide AptamersIBA 01/2021 - 06/2015
3	Cancer VaccinesIBA 01/2021 - 01/2019
3	Glutathione (Reduced Glutathione)IBA 11/2020 - 03/2019
3	Irinotecan (Camptosar)FDA LinkGeneric 06/2019 - 06/2010
3	human ERBB2 proteinIBA 10/2018 - 06/2015
3	Epirubicin (Ellence)FDA LinkGeneric 01/2016 - 10/2013
2	Amino Acids FDA Link 07/2022 - 04/2016
2	DiarylheptanoidsIBA 03/2022 - 08/2021
2	ErbB Receptors (EGF Receptor)IBA 02/2022 - 01/2018
2	fosbretabulin (combretastatin A4)IBA 02/2022 - 01/2019
2	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2022 - 12/2019
2	MicellesIBA 10/2021 - 10/2020
2	Malondialdehyde (Propanedial)IBA 10/2021 - 03/2019
2	Meglumine AntimoniateIBA 10/2021 - 05/2019
2	SesquiterpenesIBA 07/2021 - 01/2019
2	coumarinIBA 07/2021 - 01/2019
2	Hormones (Hormone)IBA 04/2021 - 04/2018
2	LeptinIBA 04/2021 - 04/2018
2	ChitosanIBA 01/2021 - 12/2018
2	peptide AIBA 01/2021 - 01/2014
2	Epithelial Cell Adhesion MoleculeIBA 01/2021 - 05/2020
2	Streptozocin (Streptozotocin)FDA Link 01/2021 - 07/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2020 - 12/2019
2	BuffersIBA 04/2020 - 12/2016
2	Cholesterol Ester Transfer ProteinsIBA 04/2020 - 07/2016
2	BCG Vaccine FDA Link 12/2019 - 01/2019
2	distearoyl phosphatidylglycerol (DSPG)IBA 08/2019 - 01/2018
2	1,2-distearoylphosphatidylethanolamine (DSPE)IBA 08/2019 - 01/2017
2	miltefosine (Impavido)IBA 08/2019 - 12/2015
2	hydroquinone (Esoterica)FDA Link 06/2019 - 09/2015
2	PCSK9 InhibitorsIBA 05/2019 - 05/2019
2	SolutionsIBA 01/2019 - 11/2009
2	Bortezomib (Velcade)FDA Link 01/2019 - 01/2019

Therapy/Procedure

40	Therapeutics 07/2022 - 10/2012
17	Immunotherapy 02/2022 - 01/2015
6	Drug Therapy (Chemotherapy) 12/2020 - 10/2013
2	Injections 07/2022 - 07/2020
2	Aftercare (After-Treatment) 01/2022 - 09/2015